Clinical characteristics and treatments of hereditary leiomyomatosis renal cell carcinoma: two case reports and literature review

Fumarate hydratase inactivation in hereditary leiomyomatosis and renal cell cancer is synthetic lethal with ferroptosis induction

(2018) Michael J. Kerins et al.   CANCER SCIENCE

Correction to: Reassessing the clinical spectrum associated with Hereditary Leiomyomatosis and Renal Cell Carcinoma syndrome in French FH mutation carriers

(2018) M. Muller et al.   CLINICAL GENETICS

Comprehensive genomic and phenotypic characterization of germline FH deletion in hereditary leiomyomatosis and renal cell carcinoma

(2017) Cathy D. Vocke et al.   GENES CHROMOSOMES & CANCER

Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report

(2016) Takao Kamai et al.   BMC CANCER

Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment

(2014) Fred H. Menko et al.   Familial Cancer

Hereditary Kidney Cancer Syndromes

(2013) Naomi B. Haas et al.   ADVANCES IN CHRONIC KIDNEY DISEASE

Uterine smooth muscle tumors with features suggesting fumarate hydratase aberration: detailed morphologic analysis and correlation with S-(2-succino)-cysteine immunohistochemistry

(2013) Carolina Reyes et al.   MODERN PATHOLOGY

An Antioxidant Response Phenotype Shared between Hereditary and Sporadic Type 2 Papillary Renal Cell Carcinoma

(2011) Aikseng Ooi et al.   CANCER CELL

Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma

(2011) B. Gardie et al.   JOURNAL OF MEDICAL GENETICS

Amplification of epidermal growth factor receptor gene in renal cell carcinoma

(2010) Iman El-Hariry et al.   EUROPEAN JOURNAL OF CANCER